<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162899</url>
  </required_header>
  <id_info>
    <org_study_id>RSJ10303</org_study_id>
    <nct_id>NCT04162899</nct_id>
  </id_info>
  <brief_title>A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel,&#xD;
      multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment&#xD;
      for patients with moderate to severe atopic dermatitis.&#xD;
&#xD;
      The study will be conducted over a 12-week treatment period. Two active doses of SHR0302 will&#xD;
      be compared to placebo and improvement in atopic dermatitis will be assessed using the&#xD;
      Investigator's Global Score (IGA)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects achieving Investigator's Global Score (IGA) response which improvement â‰¥ 2 from baseline.</measure>
    <time_frame>At week 12</time_frame>
    <description>The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of czema Area and Severity Index (EASI) change.</measure>
    <time_frame>Up to week 12</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Investigator's Global Score (IGA) Response</measure>
    <time_frame>Up to week 8</time_frame>
    <description>The IGA is a validated assessment instrument used in clinical studies to rate The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of pruritus numerical rating scale (NRS) change</measure>
    <time_frame>Up to week 12</time_frame>
    <description>The Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Active Comparator: SHR0302 dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: SHR0302 dose B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: SHR0302</intervention_name>
    <description>The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).</description>
    <arm_group_label>Active Comparator: SHR0302 dose A</arm_group_label>
    <arm_group_label>Active Comparator: SHR0302 dose B</arm_group_label>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between 18-75 years of age (inclusive), male or female, at the time of&#xD;
             informed consent&#xD;
&#xD;
          -  Moderate to severe atopic dermatitis&#xD;
&#xD;
          -  Capable of providing a signed and dated informed consent form indicating the subject&#xD;
             has been informed of all pertinent aspect of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with historical or current evidence of clinically significant cardiovascular,&#xD;
             neurological, psychiatric, renal, hepatic, immunological, gastrointestinal,&#xD;
             urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including&#xD;
             uncontrolled diabetes or thyroid disease) or hematological abnormalities that are&#xD;
             uncontrolled. Significant is defined as any disease that, in the opinion of the&#xD;
             Investigator, would put the safety of the subject at risk through participation, or&#xD;
             which would affect the efficacy or safety analysis if the disease/condition&#xD;
             exacerbated during the study&#xD;
&#xD;
          -  Subject has a current diagnosis of other active skin disease (e.g., psoriasis or lupus&#xD;
             erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the&#xD;
             evaluation of atopic dermatitis&#xD;
&#xD;
          -  Subject has a severe comorbidity that may require systemic steroids therapy or other&#xD;
             interventions or requires active frequent monitoring (e.g., unstable chronic asthma)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Xicheng</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgeng Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun. Yat- Sen Memorial Hospital, Sun. Yat- Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital Zhejiang university</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou first people's hospital, Zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang province People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Skin Disease Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first hospital of China medical university</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan provincial people's hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

